← Back to Clinical Trials
Recruiting NCT06955377

NCT06955377 Effect of Trunk Flexion on Airway Defense in Parkinson's Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06955377
Status Recruiting
Phase
Sponsor General University Hospital, Prague
Condition Parkinson Disease
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2025-02-18
Primary Completion 2028-02

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2025-02-18 with a primary completion date of 2028-02.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The main mechanisms of airway protection include a properly functioning swallowing process and a cough. Studies focusing on patients with Parkinson's disease (PD) have previously demonstrated impairments in both swallowing (dysphagia) and coughing (dystussia). Aspiration pneumonia is the leading cause of death in individuals with PD. Swallowing function is directly related to body posture. Postural abnormalities (PA) are a common symptom of PD and significantly contribute to patient disability, affect respiratory function, and reduce quality of life. Previous research has shown that more than 20% of PD patients suffer from some form of PA. Most PD patients with a forward trunk flexion angle greater than 30 degrees report specific difficulties, such as dysphagia. A link has previously been demonstrated between postural abnormalities associated with flexed posture and restrictive ventilatory impairment. It can be assumed that this restrictive ventilatory impairment, which reduces the amount of air the patient can inhale into the lungs and subsequently exhale, negatively affects the strength of voluntary cough. However, this hypothesis has not yet been verified in the mentioned patient group. The primary aim of the study will be to examine the effect of forward trunk flexion (FTF) in Parkinson's disease on the airway defense system.

Eligibility Criteria

Inclusion Criteria: * Diagnosis of Parkinson' s disease * Age ≥ 18 years Exclusion Criteria: * Unreliable performance of MIP, MEP, or grip strength measurements, for example, due to cognitive deficits (assessed by the researcher) * Inadequate lip seal * Significant deformities of the dominant hand that could affect the accuracy of grip strength measurements * Other severe neurological diseases apart from PD * History of unstable cardiovascular disease * Severe pulmonary disease

Contact & Investigator

Central Contact

Kateřina Dvořáková, MSc.

✉ katerina.dvorakova@vfn.cz

📞 +420 224 965 513

Frequently Asked Questions

Who can join the NCT06955377 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06955377 currently recruiting?

Yes, NCT06955377 is actively recruiting participants. Contact the research team at katerina.dvorakova@vfn.cz for enrollment information.

Where is the NCT06955377 trial being conducted?

This trial is being conducted at Prague, Czechia.

Who is sponsoring the NCT06955377 clinical trial?

NCT06955377 is sponsored by General University Hospital, Prague. The trial plans to enroll 100 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology